SOLIDARITY, 5,451 patient remdesivir late treatment RCT: 5% lower mortality [p=0.53] https://c19p.org/solidaritys
copied to clipboard
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15)
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50. Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 5.0% lower, RR 0.95, p = 0.53, treatment 301 of 2,743 (11.0%), control 303 of 2,708 (11.2%), NNT 464.
|
|
non-ventilated patients, 14.0% lower, RR 0.86, p = 0.13.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
SOLIDARITY et al., 10/15/2020, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 15 authors.
Late treatment
is less effective
is less effective
solidarity
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.